

13 May 2019

ASX ANNOUNCEMENT

Admedus to divest part of Infusion business

Medical technology company Admedus Ltd (ASX: AHZ) has entered into an agreement to sell part of its Infusion business to BTC Speciality Health Pty Ltd, a wholly owned subsidiary of BTC Health Limited (ASX: BTC) for \$6.3 million. This will complete the first phase of the Infusion business divestiture. Completion of the sale is subject to certain conditions being satisfied with the sale expected to complete in late May 2019.

Key terms of the sale:

- purchase price of \$6.3 million assuming a normal level of stock, debtors and employee entitlements;
- completion is subject to:
 - o a key supplier consenting to the novation of a contract;
 - o the transfer of certain key employees;
 - o BTC completing a capital raise; and
 - o no material adverse change impacting the business;
- excludes the distribution of the Arcomed line of Infusion pumps to major hospitals, which will continue to be operated by Admedus.

Admedus generated \$11 million in revenue from its ADAPT® products in 2018, and has steadily been reducing the selling, general and administration costs relative to revenue, as global sales of the ADAPT® product portfolio increases. The spin-off of Infusion will allow the company to pursue its global growth strategy to focus the business on the commercial growth and development of ADAPT®.

Once the transaction is complete, Admedus' headcount is expected to reduce by approximately 19%. Phase I of the Infusion divestiture is part of the overall company restructuring plans that are underway and that have been previously communicated to Admedus shareholders.

“The restructure will enable us to improve working capital management and reduce cash burn through reduction in headcount and focus on the ADAPT® portfolio - which is delivering revenue growth and offers significant potential for future value creation as we grow global

Admedus Limited


Registered Office:

Toowong Tower, Level 3, 9 Sherwood Rd, Toowong, Queensland 4066

Customer Service:

T: 1300 550 310 F: 1300 880 398 International: T: +61 (0)7 3152 3200 F: +61 (0)7 3152 3299

E: info@admedus.com W: admedus.com





sales and advance the TAVR device into human clinical trials,” said Mr. Paterson, Managing Director and CEO of Admedus.

ENDS

For more information, please contact:

Admedus@we-buchan.com

About Admedus Limited

Admedus (ASX: AHZ) is a medical technologies company delivering clinically superior solutions that help healthcare professionals create life-changing outcomes for patients. Our focus is on investing in and developing next-generation technologies with world-class partners, acquiring strategic assets to grow product and service offerings, and expanding revenues from our existing medical sales and distribution business. The Company has assets from research & development through clinical development and sales, marketing and distribution.

Website: www.admedus.com

Facebook: www.facebook.com/Admedus

Twitter: @Admedus

